Viking Therapeutics Faces Market Reality as VK2735 Pipeline Grows Crowded
PILLAR DIAGNOSTIC // WEEK 08
“A crowded late-stage GLP-1/GIP pipeline is capping VK2735’s addressable market, a risk the market hasn’t fully priced in, and without clear differentiation data, repricing is likely through muted uptake and pricing pressure rather than trial enrollment momentum.”
Proposed action
Trim exposure and avoid chasing near-term rallies.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
VK2735 is advancing through Phase 3 VANQUISH trials with over 4,500 patients enrolled and enrollment expected to complete in Q1 2026; the oral formulation is slated to enter Phase 3 in Q3 2026, sustaining both subcutaneous and oral development streams.
THE MAP
Structure & constraints
Obesity pharmacotherapy is entering a crowded late-stage phase, with dual GLP-1/GIP agonists enrolling over 4,500 patients in Phase 3 trials, intensifying competitive pressures in the treatment market.
THE MOOD
Consensus & positioning
Investor optimism is high around Viking’s late-stage GLP-1 weight-loss candidate VK2735, with analysts pricing in over 200% upside, highlighting its strong tolerability, potential acquisition appeal, and robust Phase 3 enrollment as drivers for a substantially higher valuation.